Tagged with Novo Nordis

Belgium Axel De Muyt, general manager & VP of Novo Nordisk Belgium and Luxembourg, recounts his journey through the pharma industry, how he has been able to revive the company’s perspectives in Belgium, and the importance of multi-stakeholder collaboration to raise awareness and education around diabetes.   We have a long-term…

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Romania Cecilia Radu of Novo Nordisk Romania shares her tumultuous four years that have seen declining market share and have culminated in launching the company’s first new product onto the market in several years. She reveals that the perception of diabetes in Romania is skewed, as more than 50 percent of…

Talent Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have moved on to new roles in their ever-expanding careers.    LATAM Expertise Pedro Galvis   Mexico is an interesting mix…

Taiwan Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that is the envy of its neighbours. Here, three country managers for pharma multinationals implanted in Taiwan give their first impressions of the market and what recommends it.    NHI: Bringing the…

Hungary Calin Galaseanu, recently appointed general manager of Novo Nordisk Hungary, elaborates on the country’s strong treatment paradigm for diabetes. He goes on to highlight Hungary’s key positioning as a strategic affiliate for Novo Nordisk in the areas of market access success and clinical trial capabilities.     Hungary is actually…

Korea Multinational pharma company managers working abroad must adapt to new cultures and develop a deep understanding of local markets. Korea is no different; here three foreign country managers give their first impressions and insights into the Korean pharma market.   Nic Horridge, Roche   As a newcomer in the land…

Taiwan All country managers of multinational pharma companies need to strike the balance between having a global outlook and adapting to local culture. For BoonHuey Ee, general manager of Merck Biopharma Taiwan, “at first glance, each country might appear to be vastly different with its own incomparable features. However, rather than…

Thailand Every generation of Novo Nordisk’s insulin portfolio is currently on the Thai Market and the affiliate is one of the fastest-growing pharma multinationals in Thailand. Upon this solid foundation, Novo is now looking to bring the company’s latest and most innovative products to Thailand, branch out into obesity treatments, and…

Korea Industry players – from Big Pharma giants to small local startups – are bringing new, innovative solutions to market in Korea in order to try and solve the country’s diabetes epidemic.   The growing prevalence of Type 2 Diabetes is becoming a global issue. According to Dr Nam Han Cho,…

Taiwan Steve Profit, general manager of Novo Nordisk Taiwan, shares a newcomers’ perspective as a recent transplant to the market from the company’s global office in Denmark. Profit goes on to share his mission to fulfil CEO Lars Fruergaard Jørgensen’s strategy of expanding beyond being a leader of diabetes at the…

Thailand Thailand is becoming an increasingly attractive location for pharma companies to conduct clinical trials, with multinationals such as Novo Nordisk and Boehringer Ingelheim conducting more and more of their global trials in the country.   We are very active in engaging Thai doctors and patients in benefiting from involvement in…